News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

SWARMS (SWARMS) fluctuated 49.5% in 24 hours: AI narrative drives trading volume surge
Bitget Pulse·2026/04/27 17:17
ZK (ZKsync) fluctuated by 57.9% in 24 hours: StakingPilot launch drives rebound from low point
Bitget Pulse·2026/04/27 17:17
LABNEW (LAB) fluctuated 40.7% in 24 hours: Whales accumulation and trading volume surge drive low-point rebound
Bitget Pulse·2026/04/27 16:30
Rayls (RLS) fluctuates 47.3% in 24 hours: trading volume surges and expectations for mainnet launch resonate
Bitget Pulse·2026/04/27 16:02
ZBT (ZEROBASE) fluctuates 68.9% in 24 hours: Trading volume surges over 400%, driving price rebound
Bitget Pulse·2026/04/27 16:02
AIAV (AIAvatar) fluctuated 600% in 24 hours: Speculative rebound driven by low liquidity markets
Bitget Pulse·2026/04/27 16:02
IAG (Iagon) fluctuates 44.9% within 24 hours: Public dispute between CEO and Cardano founder triggers market panic.
Bitget Pulse·2026/04/27 16:02
ROLL (RollX) 24-hour amplitude 51.2%: Low liquidity and trading volume amplify price volatility
Bitget Pulse·2026/04/27 16:02
GWEI (ETH Gas) fluctuated by 43.3% in 24 hours: Transaction volume surged 7 times, driving a sharp rise and fall
Bitget Pulse·2026/04/27 16:02
Flash
02:20
Gilead Sciences Q1 earnings beat expectations, but full-year EPS guidance was significantly lowered due to multiple acquisition deals.Glonghui, May 8th | Gilead Sciences announced that its first-quarter revenue increased by 4% year-on-year to $6.96 billion, exceeding the market expectation of $6.91 billion; adjusted earnings per share were $2.03, also surpassing the market expectation of $1.91. During the period, sales of the HIV treatment drug Biktarvy grew by 7% to $3.36 billion, slightly higher than the market forecast of $3.32 billion; sales of the oncology drug Trodelvy increased by 37% to $402 million. Looking ahead for the full year, Gilead Sciences raised its revenue guidance to between $30 billion and $30.4 billion. Due to acquisitions including cell therapy company Arcellx, autoimmune drug developer Ouro Medicines, and oncology drug developer Tubulis, the company now expects adjusted loss per share to be between $1.05 and $0.65, compared to the previous forecast of earnings per share between $8.45 and $8.85.
02:18
An address received 3.66 million LAB tokens, worth approximately $14.07 million, from the LAB project's multi-signature address 9 hours ago.Foresight News reports, according to monitoring by @ai_9684xtpa, an address received 3.66 million LAB, valued at approximately 14.07 million US dollars, from the LAB project's multi-signature address 9 hours ago. The source of these funds can be traced back to the LAB token deployment address. Subsequently, the address transferred 2.125 million tokens to two contract addresses, with the purpose remaining unclear for now.
02:18
Data: The average holding cost of new whales is currently at $80,300Jinse Finance reports that on May 8, according to on-chain analyst @ali_charts, the average holding cost of new whales (institutional large holders who entered within the past 155 days) is currently at $80,300. When the BTC price falls below this average cost line, these whales will be in a loss position. Bitcoin reached a high of $82,800 yesterday, then retreated below the $80,300 mark. If Bitcoin fails to hold above $80,300, this group of new whales may be motivated to sell, aiming to exit at break-even and avoid further losses. Such panic selling could create a wave of selling pressure, further driving the price down. Conversely, if Bitcoin successfully turns $80,300 into strong support, it would indicate that market selling pressure has been exhausted. Once these whales return to profitability, they will stop selling, switch to holding and observing, and look towards higher targets—this forms the logic for the start of a new upward trend.
News